European Society for Medical Oncology

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Yale School of Medicine, Neoplasm, Patient, Survival, NYSE, ESMO, III, Life, Hope, Lymph, Physician, Congress, Head, European Society for Medical Oncology, Multimedia, Senior, Disease, Risk, Cis, Pembrolizumab, Immunotherapy, University, Consultant, LI, Cancer, Randomized controlled trial, PET-CT, Diagnosis, Death, Regulatory affairs, Pharmaceutical industry

CEL-SCI presented the data for the first time at the European Society for Medical Oncology (ESMO) Congress in Spain on October 22, 2023.

Key Points: 
  • CEL-SCI presented the data for the first time at the European Society for Medical Oncology (ESMO) Congress in Spain on October 22, 2023.
  • The target population is estimated to cover ~145,000 advanced primary head and neck cancer patients globally per year.
  • Second, the Multikine target population can now be readily identified upon diagnosis, prior to surgery, using tests that physicians routinely use in cancer screenings.
  • CEL-SCI is not aware of any head and neck cancer therapy that has shown such a large 5-year survival benefit.

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Retrieved on: 
Monday, October 23, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DXD, AstraZeneca, Progression-free survival, IHC, HER2, Congress, PFS, European Society for Medical Oncology, HIV disease progression rates, ADC, Daiichi Sankyo, Risk, TSE, Breast cancer, Patient, Death, Medical imaging

Median PFS was 6.9 months in patients treated with datopotamab deruxtecan compared to 4.9 months in those treated with chemotherapy.

Key Points: 
  • Median PFS was 6.9 months in patients treated with datopotamab deruxtecan compared to 4.9 months in those treated with chemotherapy.
  • Results also showed a confirmed objective response rate (ORR) of 36.4% in patients treated with datopotamab deruxtecan compared to an ORR of 22.9% in patients treated with chemotherapy.
  • In the datopotamab deruxtecan arm, the all-grade interstitial lung disease (ILD) rate was low (3%) and the majority of events were low grade.
  • At the July 17, 2023 data cut-off, 93 patients remained on treatment with datopotamab deruxtecan and 39 remained on chemotherapy.

Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Retrieved on: 
Sunday, October 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Standard of care, SOC, NSCLC, ESMO, EDT, MSS, MOS, Medicine, Colorectal cancer, BAL, FOLFIRINOX, Conference, PD-1, BOT, Inc., CRC, Webcast, Cancer, Liver disease, Pancreatic cancer, ORR, Leiomyosarcoma, RECIST, Lung cancer, Melanoma, European Society for Medical Oncology, Patient, OS, BLA, EGFR, Sarcoma, BRAF, Pharmaceutical industry, Medical imaging, EU

“These new and updated data underscore BOT’s broad effectiveness across several advanced solid tumors, demonstrating its potential beyond first-generation immunotherapies and current treatments,” said Dr. Steven O’Day, Chief Medical Officer.

Key Points: 
  • “These new and updated data underscore BOT’s broad effectiveness across several advanced solid tumors, demonstrating its potential beyond first-generation immunotherapies and current treatments,” said Dr. Steven O’Day, Chief Medical Officer.
  • 12-month overall survival (OS) of 74% and median OS (mOS) not yet reached.
  • Subsequent data from expanded cohorts and early signals from a 230 patient Phase 2 trial is consistent with the earlier cohort of 70 patients.
  • "Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis."

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Retrieved on: 
Monday, October 23, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, DXD, EGFR, Arm, PD-L1, NSCLC, AstraZeneca, Incidence, ESMO, Progression-free survival, Trae tha Truth, Fatigue, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, Docetaxel, CRS, Doctor of Philosophy, HIV disease progression rates, R, Nausea, Lung, ADC, Daiichi Sankyo, Dor, TSE, Risk, Histology, ORR, ILD, Anemia, Platinum, Lung cancer, Weakness, Cancer, Patient, OS, Death, Toxicity, Neutropenia, UCLA Health, Medical imaging, Fine chemical, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Median PFS was 4.4 months in patients treated with datopotamab deruxtecan compared to 3.7 months with docetaxel.

Key Points: 
  • Median PFS was 4.4 months in patients treated with datopotamab deruxtecan compared to 3.7 months with docetaxel.
  • Results also showed a confirmed objective response rate (ORR) of 26.4% in patients treated with datopotamab deruxtecan compared to an ORR of 12.8% in patients treated with docetaxel.
  • Median PFS was 5.6 months in patients treated with datopotamab deruxtecan compared to 3.7 months in those treated with docetaxel.
  • At the March 29, 2023 data cut-off, 52 patients remained on treatment with datopotamab deruxtecan and 17 remained on docetaxel.

ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Principal, Neoplasm, Survival, AstraZeneca, Pneumonitis, Progression-free survival, IHC, American Society of Clinical Oncology, DOR, Thrombocytopenia, HER2, Immunohistochemistry, Congress, PFS, European Society for Medical Oncology, MD, Journal, Society, ADC, Disease, Medicine, TSE, Cancer, American Journal of Clinical Oncology, Annual general meeting, ILD, ORR, Anemia, Biliary tract, Overalls, University, Therapy, Patient, Neutropenia, ASCO, Fatigue, Pharmaceutical industry, Medical imaging, Daiichi Sankyo

Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2 expressing advanced solid tumors.

Key Points: 
  • Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2 expressing advanced solid tumors.
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • Median follow-up was 12.75 months as of the data cut-off of June 8, 2023.
  • These clinically meaningful outcomes affirm the interim DESTINY-PanTumor02 results presented earlier this year at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients

Retrieved on: 
Sunday, October 22, 2023
Oncology, Health, Surgery, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, ACT, Circulating tumor DNA, ESMO, Congress, NTRA, DFS, Disease, CRC, Risk, Recurrence, MRD, European Society for Medical Oncology, Patient, Neoplasm, DNA, Vaccine, Pharmaceutical industry, Nature Medicine

With 2,625 CRC patients and disease free survival (DFS) assessment at 24 months, this analysis includes more than twice the number of patients and significantly longer follow-up than the previously published 18-month findings.

Key Points: 
  • With 2,625 CRC patients and disease free survival (DFS) assessment at 24 months, this analysis includes more than twice the number of patients and significantly longer follow-up than the previously published 18-month findings.
  • Circulating tumor DNA (ctDNA) negative patients continued to show exceptional DFS regardless of adjuvant chemotherapy (ACT) treatment.
  • The presence of post-surgical ctDNA was the most significant prognostic factor for disease recurrence and was predictive of chemotherapy benefit.
  • Patients with ctDNA positive results had significantly lower DFS at 24 months than ctDNA negative patients (31% v. 89%, p-value

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

Retrieved on: 
Saturday, October 21, 2023
Oncology, Health, Biometrics, Health Technology, Clinical Trials, Biotechnology, Patient, Francis Crick Institute, NSCLC, University College London, ESMO, Lung cancer, Congress, PPM, Publication, Professor, Adenocarcinoma, Fear, R, UCL, Death, LUAD, Risk, Recurrence, MRD, Risk assessment, CT, Blood, PSNL, European Society for Medical Oncology, NeXT, Cancer, Neoplasm, MS, DNA, Medical imaging, MD, Chief Justice of Hungary

(Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.

Key Points: 
  • (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.
  • Lung cancer is the second most common cancer in the U.S., with an estimated 238,000 new cases and approximately 127,000 deaths forecasted for 2023.
  • For the current analysis, the teams used NeXT Personal to identify and track MRD in over 170 patients from the TRACERx cohort.
  • The study demonstrated that pre-surgical ctDNA levels with NeXT Personal could be used to classify early-stage lung cancer patients into lower- and higher-recurrence risk groups.

Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, DXD, Bevacizumab, Research, PRS, Ovarian cancer, Progression-free survival, Fatigue, CDH6, DOR, Vomiting, DCR, Diarrhea, PFS, Merck, HIV disease progression rates, Nausea, ADC, Disease, Daiichi Sankyo, Neoplasm, Sarah Cannon Research Institute, TSE, Recurrence, ILD, ORR, Anemia, Safety, European Society for Medical Oncology, Breast cancer, Patient, Appetite, PARP, Merck & Co., Medical imaging, Birth control, Pharmaceutical industry, MD

Updated results from a subgroup analysis of a first-in-human phase 1 trial showed that raludotatug deruxtecan (R-DXd) continues to demonstrate promising clinical activity in patients with heavily pretreated platinum-resistant advanced ovarian cancer.

Key Points: 
  • Updated results from a subgroup analysis of a first-in-human phase 1 trial showed that raludotatug deruxtecan (R-DXd) continues to demonstrate promising clinical activity in patients with heavily pretreated platinum-resistant advanced ovarian cancer.
  • These data were presented today during a mini-oral session ( 745MO ) at the 2023 European Society for Medical Oncology (#ESMO23).
  • “The response rate seen in these heavily pretreated patients is promising and further study of raludotatug deruxtecan in ovarian cancer is warranted.”
    The safety profile of raludotatug deruxtecan was consistent with previous reports from the phase 1 trial.
  • The median treatment duration was 18 weeks (range 3-115) and 33 patients remain on treatment with raludotatug deruxtecan.

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

Retrieved on: 
Saturday, October 21, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, ESMO, Progression-free survival, Congress, Endometrial cancer, PFS, HIV disease progression rates, Journal, Risk, American Journal of Clinical Oncology, Olaparib, European Society of Gynaecological Oncology, European Society for Medical Oncology, Patient, Death, Pharmaceutical industry

Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (

Key Points: 
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated hypophysitis occurred in 1.3% (8/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, including Grade 3 (0.5%) adverse reactions.
  • Real-World Outcomes in Patients with Advanced Endometrial Cancer: A Retrospective Cohort Study of US Electronic Health Records.

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, Appetite, DXD, PRS, PD-L1, Constipation, AstraZeneca, PD, Vomiting, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, CRS, HIV disease progression rates, TNBC, ADC, Dor, TSE, Breast cancer, ORR, ILD, Arm, Patient, Breast, Barts and The London School of Medicine and Dentistry, Fatigue, Medical imaging, Pharmaceutical industry, Daiichi Sankyo, Durvalumab

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • “These results for datopotamab deruxtecan plus durvalumab in the first-line triple negative breast cancer setting are highly encouraging, particularly the 79% objective response rate,” said Peter Schmid, MD, Barts Cancer Institute, London, United Kingdom, and investigator in the trial.
  • “Disease progression after initial treatment is a reality for patients with triple negative breast cancer, underscoring the need for more durable treatment options,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo.
  • As of the February 2, 2023 data cut-off, 29 patients (47%) remained on study treatment.